Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lengsin (LGSN) is a human protein encoded by the LGSN gene, structurally related to the glutamine synthetase (GS) superfamily, specifically the GS I branch, but it lacks enzymatic glutamine synthesis activity and is considered a pseudo-glutamine synthetase[1][2][3][5]. Lengsin is abundantly and specifically expressed in the lens, particularly in terminally differentiating secondary fiber cells, where it likely acts as a chaperone or structural component, facilitating intermediate filament reorganization and contributing to lens transparency and homeostasis[1][2][3][4][5]. Alternative splicing produces variants, one of which (splicing variant 4) is abnormally expressed in lung cancer, where it may promote cell survival and serve as a cancer antigen and potential immunotherapy target[1]. Lengsin has also been implicated as a possible genetic risk locus for major depressive disorder in a large GWAS[1]. Overall, LGSN is a lens-specific pseudo-enzyme with structural and chaperone functions essential for lens clarity, but may be co-opted as a cancer antigen or have genetic associations with neuropsychiatric conditions[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lengsin, lens protein with glutamine synthetase domain (LGSN).